Annotator® - "Tumor Identity Cards (CIT)®" Database
Head :
Ayadi Mira, CIT / Recherche
De Reyniès Aurélien , CIT / Recherche
Petel Fabien, CIT / Recherche
De Reyniès Aurélien , CIT / Recherche
Petel Fabien, CIT / Recherche
Last update : 12/08/2015 | Version : 2 | ID : 8214
| General | |
| Identification | |
| Detailed name | "Tumor Identity Cards (CIT)®" Database |
| Sign or acronym | Annotator® |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL approval - no. 1381614 |
| General Aspects | |
| Medical area |
Biology Cancer research Immunology |
| Health determinants |
Addictions Genetic Geography Lifestyle and behavior Medicine Occupation |
| Keywords | genome, methylation patterns, French National League Against Cancer, alterations, chromosomal rearrangement, gene expression, microRNA, cancer cells, personalised medicine, exons |
| Scientific investigator(s) (Contact) | |
| Name of the director | Ayadi |
| Surname | Mira |
| Address | 14 rue Corvisart |
| Phone | 01 53 55 24 00 |
| Mira.Ayadi@ligue-cancer.net | |
| Unit | CIT / Recherche |
| Organization | Ligue Nationale Contre le Cancer |
| Name of the director | De Reyniès |
| Surname | Aurélien |
| Phone | 01 53 55 24 00 |
| Unit | CIT / Recherche |
| Organization | Ligue Nationale Contre le Cancer |
| Name of the director | Petel |
| Surname | Fabien |
| Address | 14 rue Corvisart, 75013 Paris, France |
| Phone | 01 53 55 24 00 |
| Fabien.Petel@ligue-cancer.net | |
| Unit | CIT / Recherche |
| Organization | Ligue Nationale Contre le Cancer |
| Collaborations | |
| Participation in projects, networks and consortia |
Yes |
| Details | More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals. |
| Others | The CIT Programme has created a national network of clinicians, researchers and institutions |
| Funding | |
| Funding status |
Private |
| Details | CIT is a national cancer genomics programme that is established, funded and managed by the French National League Against Cancer since 2000. |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Ligue Nationale contre le Cancer (French League against Cancer) |
| Organisation status |
Private |
| Presence of scientific or steering committees |
Yes |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Longitudinal study (except cohorts) |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is is made on the basis of: |
Medication(s) taken Another treatment or procedure |
| Database recruitment is carried out as part of an interventional study |
No |
| Additional information regarding sample selection. | The CIT programme relies on a national network of researchers and clinicians, and on a set of technological platforms (molecular biology 'omics'). |
| Database objective | |
| Main objective | To comprehensively characterise and integrate cellular signals and associate them with patient history and treatments. Biological events can be genome alterations, mutations, chromosomal rearrangements, gene and miRNA expressions, methylation patterns, exon variations, etc.. As such, CIT is developing an integrated view of how cancer cells develop and function. This work forms the basis of personalised medicine that is adapted to the genomic characteristics of each tumour. CIT may then identify molecular signatures of patients who are more likely to respond well to a treatment, or whose cancer is deemed more aggressive, therefore helping MDs to choose the best treatment and care. |
| Inclusion criteria | Inclusion criteria depends on each cancer-specific project inside the CIT Programme, and relate to the biological and clinical questions raised by the PIs. Studies may involve patient monitoring within a hospital setting, or patients previously included in a prospective clinical study. Informed patient consent is obtained beforehand. Studied diseases may be paediatric tumours or adult cancers, and may apply to solid tumours or hematologic malignancies or lymphoma. Secure data access is restricted to the researchers involved in the Programme. |
| Population type | |
| Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population covered |
Sick population |
| Gender |
Male Woman |
| Geography area |
National |
| Detail of the geography area | France mainly; some european cohorts |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2000 |
| Date of last collection (YYYY or MM/YYYY) | 2015 |
| Size of the database | |
| Size of the database (number of individuals) |
[10 000-20 000[ individuals |
| Details of the number of individuals | Mid-2015, the CIT programme's database was containing histological, clinical and biological information from 13,000 anonymized patients, all types of cancer included, and 19,000 'omics' experiments (SNP/Expression/miRNA/Exon/Methylation; microarray or NGS). |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data Paraclinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Details of collected clinical data | diagnosis, stage, grade, pathological conditions, side-effects |
| Paraclinical data (detail) | Protein expression; gene mutation identification (ABCB1, AKT1, APC, BCL2, BRAF, BRCA1 / 2, CCND1, CDKN2A, CTNNB1, EGFR, ERBB2, etc.), known translocations (1p/19q) or alterations (microsatellite allelic loss, etc.). |
| Biological data (detail) | Presence of adenomas. Cellular morphology, differentiation, fibrosis, mitosis and necrosis. Percentage of tumour cells. Hyperplasia. AFP. Albumin. ALP. B2 microglobulin. Bilirubin. CEA. LDH. Metanephrine. PSA. Sedimentation rate. WBC. |
| Presence of a biobank |
Yes |
| Contents of biobank |
Whole blood Blood cells isolated Tissues Cell lines DNA DNAc/RNAm Others |
| Details of biobank content | Tumour samples. |
| Health parameters studied |
Health event/morbidity Health event/mortality Others |
| Other (detail) | relapse, metastasis, second cancer |
| Procedures | |
| Classifications used | ICD |
| Quality procedure(s) used | external ontologies and internal semi-structured vocabulary |
| Participant monitoring |
Yes |
| Links to administrative sources |
No |
| Promotion and access | |
| Promotion | |
| Link to the document | http://cit.ligue-cancer.net/?page_id=59 |
| Description | List of publications |
| Access | |
| Presence of document that lists variables and coding procedures |
Yes |
| Terms of data access (charter for data provision, format of data, availability delay) | Secure data access is restricted to the researchers involved in the CIT Programme |
| Access to aggregated data |
Access on specific project only |
| Access to individual data |
Access on specific project only |
